JACC:硝普钠会对LGSAS和保留EF患者产生哪些影响?

2017-10-10 王立群 环球医学

2017年9月,发表在《J Am Coll Cardiol》上的一项研究,调查了低梯度重度主动脉瓣狭窄(LGSAS)伴保留射血分数(EF)患者对硝普钠的急性血流动力学应答,研究结果表明:硝普钠可降低LGSAS伴保留EF患者的动脉后负荷和左心室充盈压,使得25%的患者重新分类为中度狭窄。

2017年9月,发表在《J Am Coll Cardiol》上的一项研究,调查了低梯度重度主动脉瓣狭窄(LGSAS)伴保留射血分数(EF)患者对硝普钠的急性血流动力学应答,研究结果表明:硝普钠可降低LGSAS伴保留EF患者的动脉后负荷和左心室充盈压,使得25%的患者重新分类为中度狭窄。

背景: LGSAS伴保留EF还未完全理解。动脉后负荷和舒张功能不全对LGSAS血流动力学表现的影响仍然未知。

目的:旨在确定LGSAS伴保留EF患者对硝普钠的急性血流动力学应答。

方法:进行心导管插入术的症状性LGSAS和保留EF患者,在硝普钠给药前和给药后比较了血流动力学测量。

结果:41例患者(25例低血流(LF),每搏输出量指数(SVI)≤35ml/m2,16例血流正常(NF))纳入到本研究中。基线时,LF患者具有较低的总动脉顺应性(0.36±0.12ml/m2/mmHg vs 0.48±0.16 ml/m2/mmHg;P=0.01)和较高的有效动脉弹性(2.77±0.84mmHg.m2/ml vs 1.89±0.82 mmHg.m2/ml;P=0.002)。所有患者中,硝普钠会降低弹性、左心室充盈压、肺动脉压,并改善依从性(P<0.05)。6例LF(24%)和4例NF(25%)患者的主动脉瓣区增加至≥1.0cm2。硝普钠带来的SVI改变与基线SVI成反比,仅在LF患者中证实有所改善(3±6ml/m2;P=0.02)。

结论:硝普钠可降低LGSAS伴保留EF患者的动脉后负荷和左心室充盈压,使得25%的患者重新分类为中度狭窄。基线SVI和SVI改变与后负荷降低之间具有负相关性,表明对后负荷的高度敏感性为LF-LGSAS病理生理学的显着促成因素。这些数据强调了使用后负荷降低在LGSAS的诊断性评估中的重要作用。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2007773, encodeId=5116200e7735e, content=<a href='/topic/show?id=cf4d1590956' target=_blank style='color:#2F92EE;'>#SAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15909, encryptionId=cf4d1590956, topicName=SAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sun Aug 05 09:41:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853800, encodeId=7f4c1853800bf, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Feb 23 10:41:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325553, encodeId=d9db1325553ab, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Oct 12 08:41:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630327, encodeId=d446163032e61, content=<a href='/topic/show?id=2979e3534a6' target=_blank style='color:#2F92EE;'>#硝普钠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73534, encryptionId=2979e3534a6, topicName=硝普钠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2a721492838, createdName=xuruicheng, createdTime=Thu Oct 12 08:41:00 CST 2017, time=2017-10-12, status=1, ipAttribution=)]
    2018-08-05 jiyangfei
  2. [GetPortalCommentsPageByObjectIdResponse(id=2007773, encodeId=5116200e7735e, content=<a href='/topic/show?id=cf4d1590956' target=_blank style='color:#2F92EE;'>#SAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15909, encryptionId=cf4d1590956, topicName=SAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sun Aug 05 09:41:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853800, encodeId=7f4c1853800bf, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Feb 23 10:41:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325553, encodeId=d9db1325553ab, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Oct 12 08:41:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630327, encodeId=d446163032e61, content=<a href='/topic/show?id=2979e3534a6' target=_blank style='color:#2F92EE;'>#硝普钠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73534, encryptionId=2979e3534a6, topicName=硝普钠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2a721492838, createdName=xuruicheng, createdTime=Thu Oct 12 08:41:00 CST 2017, time=2017-10-12, status=1, ipAttribution=)]
    2018-02-23 hbwxf
  3. [GetPortalCommentsPageByObjectIdResponse(id=2007773, encodeId=5116200e7735e, content=<a href='/topic/show?id=cf4d1590956' target=_blank style='color:#2F92EE;'>#SAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15909, encryptionId=cf4d1590956, topicName=SAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sun Aug 05 09:41:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853800, encodeId=7f4c1853800bf, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Feb 23 10:41:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325553, encodeId=d9db1325553ab, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Oct 12 08:41:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630327, encodeId=d446163032e61, content=<a href='/topic/show?id=2979e3534a6' target=_blank style='color:#2F92EE;'>#硝普钠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73534, encryptionId=2979e3534a6, topicName=硝普钠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2a721492838, createdName=xuruicheng, createdTime=Thu Oct 12 08:41:00 CST 2017, time=2017-10-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2007773, encodeId=5116200e7735e, content=<a href='/topic/show?id=cf4d1590956' target=_blank style='color:#2F92EE;'>#SAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15909, encryptionId=cf4d1590956, topicName=SAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sun Aug 05 09:41:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853800, encodeId=7f4c1853800bf, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Feb 23 10:41:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325553, encodeId=d9db1325553ab, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Oct 12 08:41:00 CST 2017, time=2017-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630327, encodeId=d446163032e61, content=<a href='/topic/show?id=2979e3534a6' target=_blank style='color:#2F92EE;'>#硝普钠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73534, encryptionId=2979e3534a6, topicName=硝普钠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2a721492838, createdName=xuruicheng, createdTime=Thu Oct 12 08:41:00 CST 2017, time=2017-10-12, status=1, ipAttribution=)]

相关资讯

JACC:硝普钠可以改善重度主动脉瓣狭窄患者的血流动力学水平

低梯度的重度主动脉瓣狭窄(LGSAS)伴保留型射血分数的病理机制尚未阐明,近日,在国际心血管权威杂志JACC上发表了一篇旨在硝普钠对LGSAS伴保留型射血分数患者的急性血流动力学影响的研究。本研究纳入了41例有临床症状的LGSAS伴保留型射血分数的患者(25例低血流[LF],SVI≤35 ml/m2;16例血流正常[NF]),并在接受硝普钠治疗前后对其血流动力学水平进行评估。在随访开始时,LF患者

曾庆平:二甲双胍,为何能成为长寿灵丹?

二甲双胍(metformin)是著名的降糖药,主要用来治疗2型糖尿病,但它对非酒精性脂肪肝病及癌症等多种人类疾病也有潜在治疗效果。更神奇的是,二甲双胍像热量限制一样能够延长生物的寿命,这已在线虫、大鼠和小鼠中得到证实。如此说来,二甲双胍堪称“神药”、“仙丹”! 6月2日,Science Daily网站报道了《美国科学院院报》(PNAS)刚刚在线发表的一篇最新论文,揭示二甲双胍通过“线粒体低毒

急性心力衰竭內枓冶疗现状与展望

急性心力衰竭(AHF)是指由于心脏结构或功能的异常,引起心排量的急剧降低,导致组织器官低灌注和急性淤血的一组临床综合征。临床上以急性左心衰最为常见,急性右心衰则较少见,但两者都常危及生命,必须紧急施救和治疗。值得注意的是,近来AHF病人中舒张性心力衰竭(心衰)的比例正逐年增加,尤其是在>65岁的老年人中:其预后并非以往所认为的舒张性心衰病人的预后好于收缩性心衰,而是相似。因此,对广大

Medpage:在硝酸甘油短缺的日子里

硝酸甘油短缺问题上个月一直在困扰着美国新泽西州 Awad博士和他的急诊团队。 Awad博士在接受MedPage Today采访时表示,“静脉注射硝酸甘油是我们治疗心肌梗死、高血压危象和急性失代偿性心力衰竭的主力药物。而且静脉注射硝酸甘油的替代药物很少,现存的替代药多与不良事件相关。” 现在急诊部正面临着一场噩梦:制作商货源短缺削弱了硝酸甘油供应,使得美国许多急诊研究

实用:泵药物的配置公式

        硝酸甘油 50mg + NS40ml 0.6ml/h (10ug/min)         硝普钠 50mg + NS 50ml 0.6ml/h (10ug/min)